New β-Lactamase Inhibitors Nacubactam and Zidebactam Improve the In Vitro Activity of β-Lactam Antibiotics Against Mycobacterium abscessus Complex Clinical Isolates

The new diazabicyclooctane-based β-lactamase inhibitors avibactam and relebactam improve the in vitro activity of β-lactam antibiotics against Mycobacterium abscessus complex (MABC). Here, we evaluated the in vitro activity of two newer diazabicyclooctane-based β-lactamase inhibitors in clinical development, nacubactam and zidebactam, with β-lactams against clinical isolates of MABC. Both inhibitors lowered the MICs of their partner β-lactams, meropenem (eight-fold) and cefepime (two-fold), and those of other β-lactams, similar to prior results with avibactam and relebactam.

Download data

• Downloaded 400 times
• Download rankings, all-time:
  • Site-wide: 63,365
  • In microbiology: 4,244
• Year to date:
  • Site-wide: 87,718
• Since beginning of last month:
  • Site-wide: 105,159

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide